Asenapine vs Paliperidone palmitate (Invega Sustenna)
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Schizophrenia
Shared mechanism: Dopamine D2 and serotonin 5-HT2A receptors (antagonist) · full Schizophrenia pipeline
Asenapine
Marketed by AbbVie and partners
NCT00212784 · Phase 3 · completed
This 52-week trial randomly assigned 1,225 people with schizophrenia to asenapine or to olanzapine, with participants, carers, investigators and outcome assessors all unaware of assignment. The primary measure was change in total PANSS symptom score. Asenapine improved symptoms by 21.0 points against 27.5 points for olanzapine, a difference favouring olanzapine at p<0.0001, so asenapine was less effective than its active comparator on this measure.
Reported efficacy
Change in total PANSS score at endpoint (Screening, Week 76, 100, and once every 24 weeks thereafter until endpoint): Mean PANSS total score changes during first year of treatment were - 37.0 asenapine and - 35.3 olanzapine, with further changes of 1.6 asenapine and - 0.8 olanzapine at the extension study endpoint (unclear)
Result source: NCT00212771
Paliperidone palmitate (Invega Sustenna)
Marketed by Johnson & Johnson
NCT00101634 · Phase 3 · completed
The study was randomized and double-blind, with 518 participants and a placebo comparison, and used a clinical symptom measure (change in total PANSS score) as its primary endpoint.
Next expected readout: December 2026 · NCT07493551 (registry estimate)
Reported efficacy
Part-2 (Disease Progression): Time to First Treatment Failure (From Day 1 up to 9 Months); Part 3 (Extended Disease Progression [EDP]): Change From Baseline in Cognition as Measured by the MATRICS Consensus Cognitive Battery (MCCB) Composite Score (Baseline and 18 Months); Part 3 (Disease Modification): Change From Baseline in Cognition as Measured by the MATRICS Consensus Cognitive Battery (MCCB) Composite Score (Baseline and Day 260): Treatment failure in Part II (9 months): paliperidone palmitate 29.5% vs oral antipsychotics 24.8%, P=0.377; extended 18-month analysis 28.6% vs 44.4%, P=0.080 (DREaM, Schizophr Res 2022). (missed)
Result source: NCT02431702
Results for Schizophrenia
Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.
| Key endpoint | Asenapine | Paliperidone palmitate (Invega Sustenna) |
|---|---|---|
| PANSS total, change | -25.5 vs -17.8−7.7 vs placeboNCT0119025418 other results
| -13.2 vs -2.9−10.3 vs placeboNCT0059057716 other results
|
| CGI-S, change | -1.3 vs -0.8−0.5 vs placeboNCT0119025417 other results
| -1 vs 0−1 vs placeboNCT0059057719 other results
|
| PANSS response | 39.3% vs 20.7%+18.6 vs placeboNCT010981101 other result
| —Not posted · NCT00101634 |
| PSP, change | —Not posted · NCT00212771 | 8.3 vs 1.7+6.6 vs placeboNCT0059057716 other results
|
| Relapse (% of patients) | —Not posted · NCT00212771 | —Not posted · NCT00101634 |
PANSS total, change
- Asenapine
- -25.5 vs -17.8−7.7 vs placeboNCT01190254
18 other results
- -21.7 vs -16.2 NCT01617187
- -12.2 vs -0.9 NCT01098110
- -14.2 vs -0.9 NCT01098110
- -23.7 vs -17.8 NCT01190254
- -17.4 vs -16.2 NCT01617187
- -19 vs -15.4 NCT01617187
- -17.1 vs -15.5 NCT01617187
- -14.8 vs -13.2 NCT01617187
- -12.5 vs -10.7 NCT01617187
- -9.1 vs -7.1 NCT01617187
- -4.9 vs -4.8 NCT01617187
- -17 vs -15.4 NCT01617187
- -12.3 vs -15.5 NCT01617187
- -12 vs -13.2 NCT01617187
- -9.9 vs -10.7 NCT01617187
- -7.2 vs -7.1 NCT01617187
- -4 vs -4.8 NCT01617187
- -21 vs -27.5 NCT00212784
- Paliperidone palmitate (Invega Sustenna)
- -13.2 vs -2.9−10.3 vs placeboNCT00590577
16 other results
- -11.6 vs -2.9 NCT00590577
- -8 vs -2.9 NCT00590577
- -18.6 vs -17.9 NCT00589914
- -1.8 vs -1.6 NCT03345342
- -21.8 vs -21.2 NCT01081769
- -19.5 vs -20.1 NCT01081769
- -21.7 vs -21.9 NCT01081769
- -18.5 vs -18.6 NCT01081769
- -23.5 vs -22.8 NCT01081769
- -16.2 vs -16.8 NCT01081769
- -14.5 vs -15 NCT01081769
- -24.3 vs -23.7 NCT01081769
- -12.2 vs -12.3 NCT01081769
- -9.4 vs -8.8 NCT01081769
- -4.8 vs -3.7 NCT01081769
- -25.5 vs -24.6 NCT01081769
CGI-S, change
- Asenapine
- -1.3 vs -0.8−0.5 vs placeboNCT01190254
17 other results
- -1.2 vs -1 NCT01617187
- -0.7 vs -0.2 NCT01098110
- -1.1 vs -0.8 NCT01617187
- -0.9 vs -0.8 NCT01617187
- -0.8 vs -0.7 NCT01617187
- -0.6 vs -0.5 NCT01617187
- -0.3 vs -0.3 NCT01617187
- -0.2 vs -0.2 NCT01617187
- -0.8 vs -0.2 NCT01098110
- -1.1 vs -0.8 NCT01190254
- -0.9 vs -1 NCT01617187
- -0.9 vs -0.8 NCT01617187
- -0.7 vs -0.8 NCT01617187
- -0.6 vs -0.7 NCT01617187
- -0.6 vs -0.5 NCT01617187
- -0.3 vs -0.3 NCT01617187
- -0.1 vs -0.2 NCT01617187
- Paliperidone palmitate (Invega Sustenna)
- -1 vs 0−1 vs placeboNCT00590577
19 other results
- -1 vs 0 NCT00590577
- -1 vs 0 NCT00590577
- -1.1 vs -1.1 NCT01081769
- -1 vs -1.1 NCT01081769
- -1 vs -1 NCT01081769
- -0.9 vs -1 NCT01081769
- 0 vs 0 NCT03345342
- -1 vs -1 NCT01081769
- -0.9 vs -0.9 NCT01081769
- -0.8 vs -0.8 NCT01081769
- -0.7 vs -0.8 NCT01081769
- -0.6 vs -0.6 NCT01081769
- -0.9 vs -0.9 NCT00589914
- -0.4 vs -0.5 NCT01081769
- -0.3 vs -0.3 NCT01081769
- -0.1 vs -0.1 NCT01081769
- -0.2 vs -0.3 NCT02431702
- -0.7 vs -0.7 NCT02431702
- -0.5 vs -0.4 NCT01157351
PANSS response
- Asenapine
- 39.3% vs 20.7%+18.6 vs placeboNCT01098110
1 other result
- 43.8% vs 20.7% NCT01098110
- Paliperidone palmitate (Invega Sustenna)
- —Not posted · NCT00101634
PSP, change
- Asenapine
- —Not posted · NCT00212771
- Paliperidone palmitate (Invega Sustenna)
- 8.3 vs 1.7+6.6 vs placeboNCT00590577
16 other results
- 6.1 vs 1.7 NCT00590577
- 2.9 vs 1.7 NCT00590577
- 15.2 vs 14.6 NCT01081769
- 14.7 vs 14 NCT01081769
- 14 vs 13.3 NCT01081769
- 12.9 vs 12.9 NCT01081769
- 1 vs 1.1 NCT03345342
- 12.7 vs 12.3 NCT01081769
- 11.4 vs 11.9 NCT01081769
- 9.9 vs 10.8 NCT01081769
- 7.6 vs 7.7 NCT01081769
- 8.5 vs 8.8 NCT00589914
- 4.9 vs 4.3 NCT01081769
- 7.5 vs 7 NCT02431702
- 2.5 vs 2.9 NCT02431702
- 5.8 vs 5.4 NCT01157351
Relapse (% of patients)
- Asenapine
- —Not posted · NCT00212771
- Paliperidone palmitate (Invega Sustenna)
- —Not posted · NCT00101634
- Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
- An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.
1 other shared endpoint and safety
Coverage. Asenapine: 5 of 5 rows · Paliperidone palmitate (Invega Sustenna): 5 of 5 rows. A dash means no reviewed, structured value is available for that endpoint in this indication.
| Reported metric | Asenapine Rows use multiple source trials | Paliperidone palmitate (Invega Sustenna) Rows use multiple source trials |
|---|---|---|
| PANSS Total absolute change · score No placebo or comparator arm | -11.08 score @ 52wka,b,c,d NCT01244828 · Phase 3 · registry result, not featured evidence show 1 more dose-5.48 score NCT01244828 · Phase 3 · registry result, not featured evidence | 57.4 score @ 13.14wk150 mga,b,c,d NCT01606254 · Phase 2 · registry result, not featured evidence show 3 more doses60.2 score @ 13.14wk100 mg NCT01606254 · Phase 2 · registry result, not featured evidence 60.6 score @ 13.14wk150/ 50 mg NCT01606254 · Phase 2 · registry result, not featured evidence 56.4 score @ 13.14wk50 mg NCT01606254 · Phase 2 · registry result, not featured evidence |
| Dropout rate | 44.4%5 mg twice dailye NCT01549041 · Phase 4 · registry result, not featured evidence show 23 more results16.7%10 mg daily in the evening NCT01549041 · Phase 4 · registry result, not featured evidence 54.8%5/10 mg BID NCT01142596 · Phase 3 · registry result, not featured evidence 0%5 mg BID NCT01617187 · Phase 3 · registry result, not featured evidence 1%2.5 mg BID NCT01617187 · Phase 3 · registry result, not featured evidence 49.7% NCT01244828 · Phase 3 · registry result, not featured evidence 35.2%5 mg BID NCT01098110 · Phase 3 · registry result, not featured evidence 40.1%10 mg BID NCT01098110 · Phase 3 · registry result, not featured evidence 50%Asenapine - Participants Who Were NCT01190267 · Phase 3 · registry result, not featured evidence 20.9%Asenapine - Participants Who Were NCT01190267 · Phase 3 · registry result, not featured evidence 20.8%5.0 mg BID NCT01190254 · Phase 3 · registry result, not featured evidence 17.3%2.5 mg BID NCT01190254 · Phase 3 · registry result, not featured evidence 33.7% NCT00174265 · Phase 3 · registry result, not featured evidence 50.4% NCT00145496 · Phase 3 · registry result, not featured evidence 30.4% NCT00150176 · Phase 3 · registry result, not featured evidence 15.7% NCT00265343 · Phase 3 · registry result, not featured evidence 67.7% NCT00156065 · Phase 3 · registry result, not featured evidence 0%5 mg NCT01206517 · Phase 1 · registry result, not featured evidence 33.3%10 mg NCT01206517 · Phase 1 · registry result, not featured evidence —10 mg NCT01206517 · Phase 1 · registry result, not featured evidence 0%10 mg NCT01206517 · Phase 1 · registry result, not featured evidence 25%10 mg NCT01206517 · Phase 1 · registry result, not featured evidence 0%10 mg NCT01206517 · Phase 1 · registry result, not featured evidence 0%2.5 mg NCT01206517 · Phase 1 · registry result, not featured evidence | —Part 2-Paliperidone Palmitate (PP)f NCT02431702 · Phase 3 show 16 more results—Part 3- OAP to PP (or Delayed-Star NCT02431702 · Phase 3 —Part 3-PP to PP (Extended Disease NCT02431702 · Phase 3 59.6% NCT01157351 · Phase 4 · registry result, not featured evidence —Double-blind PP6M NCT03345342 · Phase 3 · registry result, not featured evidence · Schizophrenia · phase 3 —Follow-up Phase PP6M NCT03345342 · Phase 3 · registry result, not featured evidence · Schizophrenia · phase 3 6.4% NCT01081769 · Phase 3 · registry result, not featured evidence 40.3%Paliperidone Palmitate (Double-bli NCT01299389 · Phase 3 · registry result, not featured evidence —Paliperidone Palmitate (Post-0bser NCT01299389 · Phase 3 · registry result, not featured evidence 24.8% NCT00589914 · Phase 3 · registry result, not featured evidence 44.8%150 mg eq. NCT00590577 · Phase 3 · registry result, not featured evidence 46.1%100 mg eq. NCT00590577 · Phase 3 · registry result, not featured evidence 48.1%25 mg eq. NCT00590577 · Phase 3 · registry result, not featured evidence 0%150 mg NCT01606254 · Phase 2 · registry result, not featured evidence 28.6%100 mg NCT01606254 · Phase 2 · registry result, not featured evidence 21.4%150/ 50 mg NCT01606254 · Phase 2 · registry result, not featured evidence 14.3%50 mg NCT01606254 · Phase 2 · registry result, not featured evidence |
| Discontinued due to AEs | 22.2%5 mg twice dailye NCT01549041 · Phase 4 · registry result, not featured evidence show 23 more results0%10 mg daily in the evening NCT01549041 · Phase 4 · registry result, not featured evidence 22.3%5/10 mg BID NCT01142596 · Phase 3 · registry result, not featured evidence 0%5 mg BID NCT01617187 · Phase 3 · registry result, not featured evidence 0%2.5 mg BID NCT01617187 · Phase 3 · registry result, not featured evidence 23.6% NCT01244828 · Phase 3 · registry result, not featured evidence 17%5 mg BID NCT01098110 · Phase 3 · registry result, not featured evidence 17.6%10 mg BID NCT01098110 · Phase 3 · registry result, not featured evidence 0%Asenapine - Participants Who Were NCT01190267 · Phase 3 · registry result, not featured evidence 5.1%Asenapine - Participants Who Were NCT01190267 · Phase 3 · registry result, not featured evidence 7.5%5.0 mg BID NCT01190254 · Phase 3 · registry result, not featured evidence 6.1%2.5 mg BID NCT01190254 · Phase 3 · registry result, not featured evidence 8.1% NCT00174265 · Phase 3 · registry result, not featured evidence 17.2% NCT00145496 · Phase 3 · registry result, not featured evidence 8.2% NCT00150176 · Phase 3 · registry result, not featured evidence 7.5% NCT00265343 · Phase 3 · registry result, not featured evidence 11.8% NCT00156065 · Phase 3 · registry result, not featured evidence —5 mg NCT01206517 · Phase 1 · registry result, not featured evidence —10 mg NCT01206517 · Phase 1 · registry result, not featured evidence —10 mg NCT01206517 · Phase 1 · registry result, not featured evidence —10 mg NCT01206517 · Phase 1 · registry result, not featured evidence —10 mg NCT01206517 · Phase 1 · registry result, not featured evidence —10 mg NCT01206517 · Phase 1 · registry result, not featured evidence —2.5 mg NCT01206517 · Phase 1 · registry result, not featured evidence | —Part 2-Paliperidone Palmitate (PP)f NCT02431702 · Phase 3 show 16 more results—Part 3- OAP to PP (or Delayed-Star NCT02431702 · Phase 3 —Part 3-PP to PP (Extended Disease NCT02431702 · Phase 3 2.2% NCT01157351 · Phase 4 · registry result, not featured evidence —Double-blind PP6M NCT03345342 · Phase 3 · registry result, not featured evidence · Schizophrenia · phase 3 —Follow-up Phase PP6M NCT03345342 · Phase 3 · registry result, not featured evidence · Schizophrenia · phase 3 — NCT01081769 · Phase 3 · registry result, not featured evidence 17%Paliperidone Palmitate (Double-bli NCT01299389 · Phase 3 · registry result, not featured evidence —Paliperidone Palmitate (Post-0bser NCT01299389 · Phase 3 · registry result, not featured evidence 3.1% NCT00589914 · Phase 3 · registry result, not featured evidence 8%150 mg eq. NCT00590577 · Phase 3 · registry result, not featured evidence 6.1%100 mg eq. NCT00590577 · Phase 3 · registry result, not featured evidence 6.3%25 mg eq. NCT00590577 · Phase 3 · registry result, not featured evidence 0%150 mg NCT01606254 · Phase 2 · registry result, not featured evidence 7.1%100 mg NCT01606254 · Phase 2 · registry result, not featured evidence 7.1%150/ 50 mg NCT01606254 · Phase 2 · registry result, not featured evidence 7.1%50 mg NCT01606254 · Phase 2 · registry result, not featured evidence |
| Serious AEs | 0%5 mg twice dailye NCT01549041 · Phase 4 · registry result, not featured evidence show 23 more results0%10 mg daily in the evening NCT01549041 · Phase 4 · registry result, not featured evidence 20.4%5/10 mg BID NCT01142596 · Phase 3 · registry result, not featured evidence 4.4%5 mg BID NCT01617187 · Phase 3 · registry result, not featured evidence 5.2%2.5 mg BID NCT01617187 · Phase 3 · registry result, not featured evidence 8.9% NCT01244828 · Phase 3 · registry result, not featured evidence 5.7%5 mg BID NCT01098110 · Phase 3 · registry result, not featured evidence 2.8%10 mg BID NCT01098110 · Phase 3 · registry result, not featured evidence 12.5%Asenapine - Participants Who Were NCT01190267 · Phase 3 · registry result, not featured evidence 3.6%Asenapine - Participants Who Were NCT01190267 · Phase 3 · registry result, not featured evidence 2.8%5.0 mg BID NCT01190254 · Phase 3 · registry result, not featured evidence 3.1%2.5 mg BID NCT01190254 · Phase 3 · registry result, not featured evidence 4.7% NCT00174265 · Phase 3 · registry result, not featured evidence 12.3% NCT00145496 · Phase 3 · registry result, not featured evidence 3.1% NCT00150176 · Phase 3 · registry result, not featured evidence 6.7% NCT00265343 · Phase 3 · registry result, not featured evidence 14.1% NCT00156065 · Phase 3 · registry result, not featured evidence 0%5 mg NCT01206517 · Phase 1 · registry result, not featured evidence —10 mg NCT01206517 · Phase 1 · registry result, not featured evidence 0%10 mg NCT01206517 · Phase 1 · registry result, not featured evidence —10 mg NCT01206517 · Phase 1 · registry result, not featured evidence —10 mg NCT01206517 · Phase 1 · registry result, not featured evidence —10 mg NCT01206517 · Phase 1 · registry result, not featured evidence 0%2.5 mg NCT01206517 · Phase 1 · registry result, not featured evidence | 12.8%Part 2-Paliperidone Palmitate (PP)f NCT02431702 · Phase 3 show 16 more results5.3%Part 3- OAP to PP (or Delayed-Star NCT02431702 · Phase 3 2%Part 3-PP to PP (Extended Disease NCT02431702 · Phase 3 18.6% NCT01157351 · Phase 4 · registry result, not featured evidence 5%Double-blind PP6M NCT03345342 · Phase 3 · registry result, not featured evidence · Schizophrenia · phase 3 5.5%Follow-up Phase PP6M NCT03345342 · Phase 3 · registry result, not featured evidence · Schizophrenia · phase 3 11.2% NCT01081769 · Phase 3 · registry result, not featured evidence 6.3%Paliperidone Palmitate (Double-bli NCT01299389 · Phase 3 · registry result, not featured evidence 3.9%Paliperidone Palmitate (Post-0bser NCT01299389 · Phase 3 · registry result, not featured evidence 6.8% NCT00589914 · Phase 3 · registry result, not featured evidence —150 mg eq. NCT00590577 · Phase 3 · registry result, not featured evidence —100 mg eq. NCT00590577 · Phase 3 · registry result, not featured evidence —25 mg eq. NCT00590577 · Phase 3 · registry result, not featured evidence 14.3%150 mg NCT01606254 · Phase 2 · registry result, not featured evidence 0%100 mg NCT01606254 · Phase 2 · registry result, not featured evidence 21.4%150/ 50 mg NCT01606254 · Phase 2 · registry result, not featured evidence 7.1%50 mg NCT01606254 · Phase 2 · registry result, not featured evidence |
| Most frequent reported AEs | 5 mg twice dailye daytime drowsiness 22.2% NCT01549041 · Phase 4 · registry result, not featured evidence show 19 more results10 mg daily in the evening daytime drowsiness 0% NCT01549041 · Phase 4 · registry result, not featured evidence 5/10 mg BID nasopharyngitis 21.7% schizophrenia 10.8% somnolence 10.8% NCT01142596 · Phase 3 · registry result, not featured evidence 5 mg BID insomnia 15% (placebo 13.9%) headache 8.8% (placebo 2%) anxiety 7.1% (placebo 11.9%) NCT01617187 · Phase 3 · registry result, not featured evidence 2.5 mg BID headache 10.3% (placebo 2%) insomnia 9.3% (placebo 13.9%) anxiety 7.2% (placebo 11.9%) NCT01617187 · Phase 3 · registry result, not featured evidence nasopharyngitis 21% somnolence 12.7% weight increased 12.7% NCT01244828 · Phase 3 · registry result, not featured evidence 5 mg BID akathisia 11.4% (placebo 5.2%) hypoaesthesia oral 10.9% (placebo 3.4%) insomnia 9.7% (placebo 12.1%) NCT01098110 · Phase 3 · registry result, not featured evidence 10 mg BID schizophrenia 13.8% (placebo 24.1%) somnolence 12.2% (placebo 1.7%) akathisia 10.5% (placebo 5.2%) NCT01098110 · Phase 3 · registry result, not featured evidence accidental overdose 12.5% acne 12.5% akathisia 12.5% NCT01190267 · Phase 3 · registry result, not featured evidence somnolence 14.8% headache 6.6% sedation 5.1% NCT01190267 · Phase 3 · registry result, not featured evidence 5.0 mg BID somnolence 17% (placebo 6.9%) sedation 11.3% (placebo 2%) insomnia 9.4% (placebo 5.9%) NCT01190254 · Phase 3 · registry result, not featured evidence 2.5 mg BID somnolence 20.4% (placebo 6.9%) dizziness 7.1% (placebo 1%) headache 7.1% (placebo 5.9%) NCT01190254 · Phase 3 · registry result, not featured evidence insomnia 10.6% weight increased 5.9% headache 2.4% NCT00174265 · Phase 3 · registry result, not featured evidence insomnia 17.6% somnolence 14.8% headache 13.5% NCT00145496 · Phase 3 · registry result, not featured evidence insomnia 20.1% (placebo 24.5%) somnolence 16% (placebo 17.2%) weight increased 14.4% (placebo 10.9%) NCT00150176 · Phase 3 · registry result, not featured evidence headache 5.2% influenza 5.2% schizophrenia 5.2% NCT00265343 · Phase 3 · registry result, not featured evidence insomnia 18.5% headache 10.9% parkinsonism 10.9% NCT00156065 · Phase 3 · registry result, not featured evidence 5 mg dystonia 66.7% dizziness 33.3% nausea 33.3% NCT01206517 · Phase 1 · registry result, not featured evidence 10 mg hypoaesthesia oral 50% dizziness 38.9% dysgeusia 38.9% NCT01206517 · Phase 1 · registry result, not featured evidence 2.5 mg sedation 33.3% dysgeusia 16.7% hypoaesthesia oral 16.7% NCT01206517 · Phase 1 · registry result, not featured evidence | show 16 more resultsinjection site pain 18.6% insomnia 18.6% weight increased 13.3% NCT01157351 · Phase 4 · registry result, not featured evidence weight increased 8.4% injection site pain 7.7% headache 6.7% NCT03345342 · Phase 3 · registry result, not featured evidence · Schizophrenia · phase 3 nasopharyngitis 3.7% upper respiratory tract infection 0.9% headache 0% NCT03345342 · Phase 3 · registry result, not featured evidence · Schizophrenia · phase 3 weight increased 15.4% insomnia 11.2% headache 10.6% NCT01081769 · Phase 3 · registry result, not featured evidence insomnia 17% (placebo 15.2%) injection site pain 13.2% (placebo 6.7%) nasopharyngitis 12.6% (placebo 6.1%) NCT01299389 · Phase 3 · registry result, not featured evidence nasopharyngitis 8.4% (placebo 6.1%) constipation 5.2% (placebo 5.5%) insomnia 3.9% (placebo 15.2%) NCT01299389 · Phase 3 · registry result, not featured evidence insomnia 9.4% headache 7.1% somnolence 5.6% NCT00589914 · Phase 3 · registry result, not featured evidence 150 mg eq. injection site pain 8% (placebo 3.7%) headache 6.1% (placebo 7.3%) akathisia 5.5% (placebo 4.9%) NCT00590577 · Phase 3 · registry result, not featured evidence 100 mg eq. headache 6.7% (placebo 7.3%) injection site pain 6.1% (placebo 3.7%) akathisia 4.8% (placebo 4.9%) NCT00590577 · Phase 3 · registry result, not featured evidence 25 mg eq. headache 10.6% (placebo 7.3%) injection site pain 8.8% (placebo 3.7%) akathisia 1.3% (placebo 4.9%) NCT00590577 · Phase 3 · registry result, not featured evidence 150 mg blood prolactin increased 92.9% insomnia 28.6% nasopharyngitis 28.6% NCT01606254 · Phase 2 · registry result, not featured evidence 100 mg blood prolactin increased 64.3% psychiatric symptom 42.9% nasopharyngitis 28.6% NCT01606254 · Phase 2 · registry result, not featured evidence 150/ 50 mg blood prolactin increased 71.4% nasopharyngitis 28.6% alanine aminotransferase increased 21.4% NCT01606254 · Phase 2 · registry result, not featured evidence 50 mg blood prolactin increased 78.6% nasopharyngitis 35.7% psychiatric symptom 35.7% NCT01606254 · Phase 2 · registry result, not featured evidence |
Notes
- aThis study reports multiple eligible drug arms; no representative arm has been reviewed.
- bTrial phases differ: Phase 2 versus Phase 3.
- cPopulation comparability has not been reviewed for both studies.
- dTreatment context has not been resolved for both arms.
- ePopulation comparability has not been reviewed for these studies.
- fPopulation comparability has not been reviewed for 15 of these studies.
Reported by one asset only
Endpoints only one of the selected assets measured, so there is nothing to compare them against.
Asenapine
show 1 more result
show 1 more result
show 17 more results
show 2 more results
show 19 more results
show 15 more results
show 15 more results
show 17 more results
show 17 more results
show 17 more results
show 17 more results
show 17 more results
+ 31 further endpoints in the CSV export.
Paliperidone palmitate (Invega Sustenna)
show 2 more results
show 3 more results
show 16 more results
show 1 more result
show 1 more result
show 1 more result
show 1 more result
show 1 more result
show 1 more result
show 1 more result
+ 16 further endpoints in the CSV export.
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Asenapine's landscape · Paliperidone palmitate (Invega Sustenna)'s landscape